Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ 231,962
▲ 247% vs 2024
Profit
Caution€ -921,288
▼ 11% vs 2024
Debts
Low€ 587,779
▼ 26% vs 2024
Inhatarget Therapeutics from Charleroi, company number BE0732994752, closed financial year 2025 with a result of € -921,288 after tax. For that financial year Inhatarget Therapeutics recorded a gross margin of € 231,962 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € -832,636 to € -921,288. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.
What happened at Inhatarget Therapeutics?
What happened at Inhatarget Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 921,288. Source: NBB ↗
- GENFLOW BIOSCIENCES became a director. NBB
- Mohamed Sebti became a director. NBB
- Karim Amighi became a director. NBB
- SAMBRINVEST & FREMOLUC HOLDING became a director. NBB
- S.M.B. TECHNOLOGY became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 1 million loss in 2021 to € 921,288 loss in 2025.
Paid € 349 in corporate taxes since 2021.
On average € 44,600 of value added per employee in 2025.
A new publication or filing at Inhatarget Therapeutics? We notify you, reason included.
Follow Inhatarget TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Inhatarget Therapeutics are FDC CONSULT, Mohamed Sebti, 50°North Ventures SRL, S.M.B. TECHNOLOGY, Karim Amighi and GENFLOW BIOSCIENCES. The same people are also behind Calysta, EEBIC, BE ANGELS, Brussels South Charleroi BioPark Dev and THEODORUS III.
Directors
According to the 2025 annual accounts
since 2019
Mohamed Sebti
Director
since 2020
Director · represented by Jean Van Nuwenborg
Also active at: EEBIC, BE ANGELS, Brussels South Charleroi BioPark Dev +18 more
since 2019
Director · represented by Arthur Deboek
since 2019
Karim Amighi
Director
since 2020
GENFLOW BIOSCIENCES
Director · represented by Eric Leire
since 2020
SAMBRINVEST & FREMOLUC HOLDING
Director · represented by Cédric Szpirer
since 2020
Establishments
Establishment units
Physical locations of this company
Rue Antoine de Saint-Exupéry 2
6041 Charleroi
Rue Auguste Piccard 48
6041 Charleroi
Active since 29 August 2019
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
DIGICLOUD COMMUNICATION
€ 569,887 gross margin · 2025
MONKEY BRIDGE
€ 290,813 gross margin · 2025
eCADE
€ -602 gross margin · 2024
MADEMOISELLE JO
€ 89,371 gross margin · 2025
BANANA NAVY
€ 82,010 gross margin · 2025
+6 more
Details
- Company number
- 0732.994.752
- VAT number
- BE 0732.994.752
- Registered office
- Rue Antoine de Saint-Exupéry 2, 6041 Charleroi
- Names & denominations
- Inhatarget Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 2019
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- info@inhatarget.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten